Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACER Acer Therapeutics (ACER) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Acer Therapeutics Stock (NASDAQ:ACER) 30 days 90 days 365 days Advanced Chart Ad Manward PressShocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company Get Acer Therapeutics alerts:Sign Up Key Stats Today's Range$0.66▼$0.8550-Day Range$0.66▼$0.9052-Week Range$0.55▼$4.56Volume574,600 shsAverage VolumeN/AMarket Capitalization$16.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Read More… Shocking: One AI startup's revenue could surge 4,735% (Ad)Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company Receive ACER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACER Stock News HeadlinesAcer Therapeutics Inc (OTC:ACER) Stock Quotes, Forecast and News SummaryAugust 16, 2024 | benzinga.comAnumana Appoints Harry S. Palmin as CFOMay 14, 2024 | tmcnet.comOil Prices Surge Due to Israel-Iran ConflictHeightened tension in the Middle East has created a huge supply shock to the global oil industry. But… I’ve found a new way to invest in oil right here in the US.October 9, 2024 | The Oxford Club (Ad)Vehicle crashes into North Avenue restaurantMay 1, 2024 | msn.comArrest made following shots fired incident on Vann AvenueApril 30, 2024 | msn.comZevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024April 29, 2024 | finanznachrichten.de2 hospitalized after double shooting on Hudson Avenue in RochesterApril 28, 2024 | msn.comFBI was on scene of incident in Portsmouth on Broomhill AvenueApril 27, 2024 | msn.comSee More Headlines ACER Stock Analysis - Frequently Asked Questions How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc. (NASDAQ:ACER) posted its earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. Does Acer Therapeutics have any subsidiaries? The following companies are subsidiaries of Acer Therapeutics: Opexa Therapeutics Inc.. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN) and VBI Vaccines (VBIV). Company Calendar Last Earnings11/19/2021Today10/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACER CUSIPN/A CIK1069308 Webwww.acertx.com Phone(844) 902-6100Fax281-872-8585Employees30Year Founded2013Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.26 million Price / Sales12.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-0.63Miscellaneous Outstanding Shares24,460,000Free Float19,963,000Market Cap$16.15 million OptionableNot Optionable BetaN/A Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ACER) was last updated on 10/9/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored$20 = Ounce of Gold?I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It'...Monument Traders Alliance | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredAI Expert Reveals New PickYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Pl...The Oxford Club | SponsoredThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in...Manward Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acer Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acer Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.